Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo - Use of the human tyrosinase promoter with human enhancers

Cancer Gene Therapy

Volumn 12, Issue 11, 2005, Pages 864-872

  Lillehammer, Trine ^a,b   Tveito, Siri ^a   Engesaeter, Birgit O ^a   Fodstad, Oystein ^a   Maelandsmo, Gunhild M ^a   Engebraaten, Olav ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adenovirus; Human tyrosinase promoter; Melanoma; Quantitative real time RT PCR; SV40 hybrid promoter; Transcriptional targeting

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER THERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE ACTIVITY; GENE CONSTRUCT; GENE EXPRESSION; HUMAN; HUMAN CELL; HYBRID GENE; IN VITRO STUDY; IN VIVO STUDY; INSTRUMENTATION; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SIMIAN VIRUS 40; TISSUE SPECIFICITY; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ENHANCER ELEMENTS (GENETICS); FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MELANOMA; MONOPHENOL MONOOXYGENASE; PROMOTER REGIONS (GENETICS); SIMIAN VIRUS 40; SKIN NEOPLASMS; TISSUE DISTRIBUTION; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS; SIMIAN VIRUS 40;

EID: 27144510148     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700852     Document Type: Article

References (24)

1. Nakamura T, Sato K, Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther. 2002;13:613-626.
2. Nettelbeck D, Rivera AA, Kupsch J, et al. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer. 2004;108:136-145.
3. Siders W, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 1996;56:5638-5646.
4. Nettelbeck DM, Jèrôme V, Müller R. Gene therapy - designer promoters for tumour targeting. Trends Genet. 2000;16:174-181.
5. Shi C-X, Hitt M, Ng P, Graham FL. Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther. 2002;13:211-224.
6. Peter I, Graf C, Dummer R, Schaffner W, Greber UF, Hemmi S. A novel attenuated replication-competent adenovirus for melanoma therapy. Gene Therapy. 2003;10:530-539.
7. Nettelbeck D, Jerome V, Müller R. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Therapy. 1999;6:1276-1281.
8. Park BJB, CK A, Hu Y, et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther. 1999;10:889-898.
9. Nettelbeck D, Rivera AA, Balaguè C, Alemany R, Curiel DT. Novel oncolytic adenovirus targeted to melanoma; specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 2002;62:4663-4670.
10. Zhang L, Akbulut H, Tang Y, et al. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytotoxic for breast cancer and melanoma. Mol Ther. 2002;6:386-393.
11. Liu Y, Ye T, Sun D, Maynard J, Deisseroth A. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum Gene Ther. 2004;15:637-647.
12. Banerjee N, Rivera AA, Wang M, et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther. 2004;3: 437-449.
13. Fodstad O, Kjonniksen I, AAmdal S, Nesland JM, Boyd MR, Pihl A. Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res. 1988;48:4382-4388.
14. AAmdal SFO, Pihl A. Human tumor xenografts transplanted under the renal capsule of conventional mice. Growth rates and host immune response. Int J Cancer. 1984;34:725,730.
15. Kjonniksen IRP, Fodstad O. Helix pomatia agglutinin binding in human tumor cell lines: correlation with pulmonary metastases in nude mice. J Cancer. 1994;69:1021-1024.
16. Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A. A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer. 1988;41:442-449.
17. Fodstad O, Brogger A, Bruland O, Solheim OP, Nesland JM, Pihl A. Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. Int J Cancer. 1986;38:33-40.
18. He T-C, Zhou S, Da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509-2514.
19. Shariatmadari R, Sipila PP, Huhtaniemi IT, Poutanen M. Improved technique for detection of enhanced green fluorescent protein (EGFP) in transgenic mice. BioTechniques. 2001;30:1282-1285.
20. Diaz R, Eisen T, Hart IR, Vile RG. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol. 1998;72:789-795.
21. Brooks ARHR, Wang P, Qian HS, Liu P, Rubanyi GM. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med. 2004;6:395-404.
22. Papadakis EDNS, Baker AH, White SJ. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther. 2004;4:89-113.
23. Gaggioli CBR, Abbe P, Ortonne J-P, Ballotti R. Microphtalmia-associated transcription factor (MITF) is required but is not sufficient to induce the expression of melanogenic genes. Pigment Cell Res. 2003;16:374-382.
24. Okada Y, Okada N, Nakagawa S, et al. Tumor necrosis factor alpha-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors. Jpn J Cancer Res. 2002;93:436-444.